stockrowFortress Biotech, Inc.
FBIO Healthcare Biotechnology
Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −116.0%
- Free cash flow
- −115.4%
- Total debt
- −35.7%
Quarter to June 2026, against a year earlier
Follow FBIO
Alert me
Fortress Biotech, Inc. (FBIO) EV/Sales
As of 6 November 2026, Fortress Biotech, Inc. (FBIO) trades at a EV/Sales of −1.5×. Over the past ten years it has ranged from −5.8× (April 2018) to 68.3× (April 2016); the current reading is higher than 6% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.2× | 38.08% |
| FY2024 | 0.9× | 596.45% |
| FY2023 | 0.1× | — |
| FY2022 | −0.3× | — |
| FY2021 | −0.8× | — |
| FY2020 | 1.2× | (52.20%) |
| FY2019 | 2.6× | 375.24% |
| FY2018 | 0.5× | (89.27%) |
| FY2017 | 5.1× | 80.94% |
| FY2016 | 2.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −0.9× | — |
| Mar 2026 | −1.9× | — |
| Dec 2025 | 1.2× | 17.55% |
| Sep 2025 | 1.1× | 114.15% |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TENX Tenax Therapeutics, Inc. compare | −93.0× |
| FBIO Fortress Biotech, Inc. | −1.5× |
| CNXU Conexeu Sciences Inc. compare | n/m |
| CGTX Cognition Therapeutics, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| SPRO Spero Therapeutics, Inc. compare | 0.2× |
| CRDF Cardiff Oncology, Inc. compare | 39.8× |
| NORD Nordicus Partners Corporation compare | 79.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)